| Period | 22 Mar 2017 |
|---|---|
| Event type | Conference |
| Location | Porto, PortugalShow on map |
| Degree of Recognition | International |
Related content
-
Research Outputs
-
A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures
Research output: Contribution to Journal › Article › peer-review
-
Dystrophin quantification: biological and translational research implications
Research output: Contribution to Journal › Article › peer-review
-
Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to Exon 44 or 45 skipping
Research output: Contribution to Journal › Article › peer-review
-
Impacts
-
FDA approves first drug to treat Duchenne muscular dystrophy (DMD)
Impact: Public policy impacts, Health and Well-Being impacts, Quality of life impacts, 03: Good Health and Well-Being (UN SDG)